12th BioVaria to take place on 8 – 9 May 2019 in Munich
MUNICH--(BUSINESS WIRE)--Apr 4, 2019--On 8–9 May 2019, decision makers from biotech, pharma and finance will come together in Munich for the 12 th BioVaria to learn about commercially attractive academic inventions and initiate partnerships with research teams, entrepreneurs and technology transfer professionals from all over Europe.
66 peer-selected, patent-protected technologies originating from as many research institutes, universities and university hospitals will be featured.
Further program highlights include a panel discussion on “From stem cells to therapy: Development of cell based approaches in regenerative medicine” and BioVaria’s dedicated Startup Pitch & Partner program. The expanded format of the Startup Pitch & Partner program provides attractive opportunities for entrepreneurs and venture capitalists, with interactive pitches, one-on-one mentoring sessions and speed dating between startups and investors. Based on last year’s success it attracted more applications from European startups than ever before. A preview of all technologies selected for BioVaria 2019 and the startups selected for this year’s Startup Pitch & Partner program is available online.
BioVaria is organised by Ascenion and 14 additional technology transfer organisations from 5 European nations.
Preview BioVaria’s Technologies and Startups online
- Explore the technologies presented in 10-min oral presentations and posters
- Get a first impression of the participating startups
Register now at www.biovaria.org
Who should attend?
- Scouts and business developers from the international biopharmaceutical industry looking for cutting-edge inventions to complement their companies’ R&D portfolios
- Life-science investors looking for attractive startups or IP assets as investment opportunities
- Technology transfer professionals and scientists from public research institutions who have patent-protected technologies available for licensing or partnering
Bavarian Ministry of Economic Affairs, Regional Development and Energy
Bio M, Abbvie, Else Kröner-Fresenius-Stiftung, ISAR Bioscience, Johnson & Johnson Innovation, HERTIN & Partner, Kador & Partner, NLC, Vossius & Partner
24IP Law Group, Accelero Bioanalytics, Charles River, German Accelerator Life Sciences, IASON Consulting, K&L Gates, LSI Life Science Inkubator, LSP, ttopstart, TVM Capital Life Science
Technology transfer partners:
Ascenion, Austria Wirtschaftsservice Gesellschaft, BayPAT, DKFZ - German Cancer Research Center, DZIF - German Center for Infection Research, EMBLEM Technology Transfer, IOCB Tech, Lead Discovery Center, LMU Munich, Max Planck Innovation, Netval, PROvendis, TechnologieAllianz, University of Pardubice, VIS
ASTP-Proton, BIO Deutschland, BioRN
Business Wire, Going Public, LABIOTECH.eu, transkript
View source version on businesswire.com:https://www.businesswire.com/news/home/20190404005356/en/
CONTACT: Ascenion GmbH
KEYWORD: AUSTRIA EUROPE GERMANY SWITZERLAND
INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT HEALTH BIOTECHNOLOGY PHARMACEUTICAL PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES
SOURCE: Ascenion GmbH
Copyright Business Wire 2019.
PUB: 04/04/2019 07:22 AM/DISC: 04/04/2019 07:22 AM